NCT05874180已完成1 期
A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Fixed-dose Combination of DW6013 and Loose Combination of Each Component in Healthy Adult Volunteers in Fed Condition
Dong Wha Pharmaceutical Co. Ltd.1 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2023年1月9日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 31
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6013 and each component in healthy adult volunteers in fed condition.
详细描述
This is a Phase 1, randomized, open-label, Oral, Single-dose, two-way crossover study in healthy subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects aged up to 19 years
- •Subjects weighing at least 50.0 kg and no more than 100 kg (inclusive) with a BMI between 18.5 kg/m2 and 30.0 kg/m2
- •Subjects with neither congenital nor chronic diseases requiring treatment, and no abnormal symptoms or findings upon medical examination
- •Subjects considered eligible for the study participation in accordance to the results of clinical laboratory tests, vital signs, physical examinations and 12-lead ECG conducted at the time of screening, based on the investigational product (IP) characteristics
- •Subjects who has a full understanding in participation of the study, voluntarily provide a written consent in participation, and give full agreement in following the subject guidelines throughout the entire study period
排除标准
- •Subjects with any clinically significant hepatic, renal, nervous, respiratory, endocrine, circulatory, tumor, genitourinary, cardiovascular, digestive, musculoskeletal systemic diseases or other medical history
- •Pregnant subjects with a positive urine HCG test, or lactating female subjects
- •Subjects taking drugs known to significantly induce or inhibit drug metabolizing enzymes, including barbitals within 1 months prior to the first IP administration
- •Subjects with clinically significant 12-lead ECG findings at the time of screening
- •Subjects with a past history of drug abuse or a positive urine drug test
- •Subjects with SBP ≥ 150 mmHg or ≤ 90 mmHg; DBP ≥ 100 mmHg or ≤ 60 mmHg; PR ≤ 40 bpm or ≥ 100 bpm at the time of screening
- •Subjects following an unusual diet or consumption of food which may affect the absorption, distribution, metabolism and excretion of the IP
- •Subjects who have administered any prescription drugs or herbal medicines that may affect the characteristics of clinical investigational drugs within 2 weeks prior to the first administration date, or have administered any over-the-counter (OTC) or vitamin preparations within 10 days
- •Subjects who have participated and were given any other study drugs in other clinical study within 6 months prior to the first IP administration
- •Subjects who have consistently drunk alcohol within 6 months
- •Subjects who have smoked more than 10 cigarettes/day on average
- •Subjects who have eaten or cannot refrain from eating grapefruit (grapefruit)-containing food from 48 hours before the first administration until the time of PSV
- •Subjects who have consumed or cannot refrain from consuming caffeine-containing food during the period from 24 hours prior to administration of each period to the time of the last blood sampling
- •Subjects who have done and are unable to refrain from strenuous activity
- •Subjects who are planning for pregnancy or not willing to use a medically reliable forms of contraception
- •Subjects otherwise considered ineligible for participation due to other reasons including clinical laboratory test results not mentioned in the inclusion/exclusion criteria at the investigator's discretion
研究组 & 干预措施
Sequence A
Experimental
Period 1: Linagliptin and Metformin / Period 2: DW6013
干预措施: DW6013 (Drug)
Sequence B
Experimental
Period 1: DW6013 / Period 2: Linagliptin and Metformin
干预措施: DW6013 (Drug)
结局指标
主要结局
Cmax
时间窗: up to 48 hours
Cmax of Metformin
AUC0-t
时间窗: up to 48 hours
AUC0-t of Metformin
次要结局
- t1/2(up to 48 hours)
- AUCinf(up to 48 hours)
- CL/F(up to 48 hours)
- Tmax(up to 48 hours)
- Vd/F(up to 48 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component(Empagliflozin and Metformin) in Healthy Adult Volunteers in Fast Condition.Healthy SubjectsNCT05823870Dong Wha Pharmaceutical Co. Ltd.32
已完成
1 期
A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult VolunteersHealthy SubjectsNCT05874167Dong Wha Pharmaceutical Co. Ltd.50
尚未招募
1 期
This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component in Healthy Adult Volunteers in Fed Condition.DW6014NCT05823883Dong Wha Pharmaceutical Co. Ltd.30
已完成
1 期
A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult VolunteersHealthy SubjectsNCT05403281Dong Wha Pharmaceutical Co. Ltd.41
已完成
1 期
A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult VolunteersHealthy SubjectsNCT05236998SK Chemicals Co., Ltd.45